• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ELI LILLY AND COMPANY HUMAPEN SAVVIO 3ML (GRAY); FOR TREATMENT PURPOSES

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ELI LILLY AND COMPANY HUMAPEN SAVVIO 3ML (GRAY); FOR TREATMENT PURPOSES Back to Search Results
Model Number MS9699
Device Problem Device Operates Differently Than Expected (2913)
Patient Problem Hyperglycemia (1905)
Event Type  Injury  
Manufacturer Narrative
New updated and corrected information is referenced within the update statements in describe event or problem.No further follow up is planned.
 
Event Description
(b)(4).This solicited case, reported by a consumer via a patient support program (psp), concerns a 49 years old male patient of unknown ethnicity.Medical history included vision reduced.Concomitant medications were not provided.The patient received insulin lispro (rdna origin) injection (humalog) cartridge, 10 iu daily, and also insulin glargine injection (basaglar) cartridge, 18 iu daily, both via unknown route of administration, for unknown indication, beginning on an unknown date.On an unspecified date, unknown time after beginning insulin lispro and insulin glargine via humapen savvio gray (lot 1411v01), the injection button was not doing the click sound and the injection screw was not going further ((b)(4) / lot number 1411v01).Due to this, the patients glycemia did not decrease and got higher, up to almost 500, considered serious by the company due to medical significance.The patient was reported to have trouble injecting due to his reduced vision and it was informed that a patient with vision impairment should have help from a trained user for injection.Additional information regarding corrective treatments and outcomes was not provided.It was unknown if insulin lispro and insulin glargine therapies were continued.The device was operated by the patient, however it was unknown if he received training and how long the operator had used the device model.The reported device was in use for over three years.The suspect device was not returned to the manufacturer.The reporting consumer considered the event related to insulin lispro, insulin glargine and to the device.Update 07mar2018: additional information received on 05mar2018 from the initial reporting consumer.No new information was provided.Update 12mar2018: additional information received on 08mar2018 from the initial reporting consumer via psp.Added patient email and phone number.Added vision reduced as medical history.Changed humapen unknown device to humapen savvio.Added humapen savvio lot.Changed humapen savvio improper use from no to yes and operator from unknown to lay user/patient.Changed blood glucose increased to serious event.Updated narrative and corresponding fields accordingly.Edit 15mar2018: updated medwatch and european and canadian (eu/ca) fields for expedited device reporting.No new information added.Edit 16mar2018: upgraded case priority and updated european and canadian (eu/ca) fields.Update 19mar2018: additional information received on 19mar2018 from the initial reporting consumer.Changed humapen savvio preliminary comments to usage concerns resolved, and device was reported to be working properly.Added humapen savvio device age.Added basaglar dosing regimen.Updated narrative and corresponding fields accordingly.Update 22mar2018: additional information received on 21mar2018 from the global product complaint database.Entered device specific safety summary (dsss); updated the medwatch and european and canadian (eu/ca) device fields; added date of manufacturer for the suspect humapen savvio (gray) device associated with pc 4293820.Corresponding fields and narrative updated accordingly.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
HUMAPEN SAVVIO 3ML (GRAY)
Type of Device
FOR TREATMENT PURPOSES
Manufacturer (Section D)
ELI LILLY AND COMPANY
lilly corporate center
indianapolis IN 46285
Manufacturer (Section G)
ELI LILLY AND COMPANY
lilly corporate center
indianapolis IN 46285
Manufacturer Contact
chris davis
lilly corporate center
indianapolis, IN 46285
3174334585
MDR Report Key7399214
MDR Text Key104469057
Report Number1819470-2018-00040
Device Sequence Number1
Product Code FMF
Combination Product (y/n)N
PMA/PMN Number
K160668
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,consum
Type of Report Initial
Report Date 04/05/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Lay User/Patient
Device Model NumberMS9699
Device Lot Number1411V01
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 03/08/2018
Initial Date FDA Received04/05/2018
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured11/30/2014
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age49 YR
-
-